Korean Market
EXCH
SK Biopharmaceuticals
★

SK Biopharmaceuticals Discloses 2026 Corporate Governance Report – Strong Governance with Majority Outside Directors and All-Outside Audit Committee, No Dividend

 
FTC
SK Biopharmaceuticals
★

SK Biopharmaceuticals Discloses Corporate Group Status: Solid Financials, Top Shareholder SK Holdings Maintains Stable 50.08% Stake

 
EXCH
SK Biopharmaceuticals
★

SK Biopharmaceuticals Signs Supply Agreement with Subsidiary for Cenobamate... No Impact on Consolidated Financials

 
EXCH
SK Biopharmaceuticals
★

Announcement of Domestic NDR... Q1 2026 Earnings and Business Update to Be Presented, No Direct Impact on Shareholder Value

 
EXCH
SK Biopharmaceuticals
★

Investor Relations (IR) Event - Domestic NDR

 
PERI
SK Biopharmaceuticals
★★★

SK Biopharmaceuticals Q1 2026: Operating Profit of KRW 89.8B on Strong Cenobamate Sales

 
EXCH
SK Biopharmaceuticals
★

IR Conference Call for 2025 Q4 and Annual Earnings

 
EXCH
SK Biopharmaceuticals
★★★★

SK Biopharm Q1 2026 Results: Revenue and Operating Profit Surge, Net Income Up 423.5% YoY

 
EXCH
SK Biopharmaceuticals
★

2026 Q1 Earnings Results IR Meeting